Modulation of Human Platelet Aggregation by the Phosphodiesterase Type 5 Inhibitor Sildenafil
Authors:
- Reinhard BerkelsRBReinhard Berkels
- Theo KlotzTKTheo Klotz
- Guido StichtGSGuido Sticht
- Udo EnglemannUEUdo Englemann
- Wolfgang KlausWKWolfgang Klaus
- 1 April 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 37 (4) , 413-421
Abstract
The aim of this study was to investigate if the phospodiesterase type 5 inhibitor sildenafil inhibits collagen-or ADP-induced human platelet aggregation and bleeding time. To investigate this, two studies were designed. In the first, a single oral dose of sildenafil, 100 mg, was administered to healthy men. Bleeding time was determined and agonist (ADP and collagen)-induced platelet aggregation (ex vivo in platelet rich plasma) was measured 0, 1, and 4 h after application. In the second, a single oral dose of sildenafil, 50 mg, was administered and, in addition to the parameters in the first study, we also determined the platelet aggregation after 24 h and measured the effect of a nitric oxide donor (S-nitroso-N-acetylpenicillamine [SNAP]) in combination to mimic a physiologic nitric oxide release from the endothelium. The bleeding time of 1 h after sildenafil medication (100 mg) was significantly prolonged but recovered toward control values after 4 h, whereas application of sildenafil at a lower dose (50 mg) did not alter the bleeding time. Sildenafil (100 and 50 mg) did not inhibit the ADP-induced aggregation, whereas the collagen-induced aggregation (100 mg) was markedly reduced after 1 h and significantly inhibited 4 h after application. This inhibitory effect was overcome by higher concentrations of collagen. SNAP (0.5 μM) induced an inhibition of platelet aggregation that was potentiated after taking sildenafil (50 mg, 1 and 4 h afterward) and abrogated after 24 h. These data indicates that sildenafil may inhibit collagen-induced platelet aggregation ex vivo. After co-administration of nitric oxide, collagen-and ADP-induced platelet aggregation was significantly inhibited, which may reflect physiologic conditions of an in vivo system.Keywords
This publication has 27 references indexed in Scilit:
- Benefit of Clopidogrel in Patients with Evidence of Cerebrovascular DiseaseNeurology, 1998
- Oral Sildenafil in the Treatment of Erectile DysfunctionNew England Journal of Medicine, 1998
- Characterization of the Isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021Cellular Signalling, 1996
- Direct Measurement of Nitric Oxide Production in Platelets: Relationship with Cytosolic Ca2+ ConcentrationBiochemical and Biophysical Research Communications, 1995
- Diversity in Cyclic Nucleotide Phosphodiesterase Isoenzyme FamiliesArchives of Biochemistry and Biophysics, 1995
- Role of Nitric Oxide in the Physiology of Erection1Biology of Reproduction, 1995
- Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetesThrombosis Research, 1994
- Direct Electrochemical Measurement of Nitric Oxide Released from Human PlateletsBiochemical and Biophysical Research Communications, 1993
- Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymesTrends in Pharmacological Sciences, 1991
- Aggregation Response of Human Platelets Stored at 22 C as Platelet‐Rich PlasmaTransfusion, 1979